Merck Millipore Launches Kit for Analyzing NFкB Translocation by Imaging Flow Cytometry
• Permits quantitative, statistically robust assessment of NFкB translocation
• Allows for analysis at single-cell level
• Optimized and designed for Amnis® imaging flow cytometers
Darmstadt, November 19, 2014 - Merck Millipore, the Life Science division of Merck, today introduced the Amnis® NFкB Translocation kit, which allows researchers to better study the nuclear translocation of NFкB, a transcription factor that plays a central role in regulating key mammalian cell processes, including proliferation, inflammation, immune and stress responses. The new kit uses imaging flow cytometry to obtain statistically significant quantitative assessment of NFкB translocation, as well as visual identification of the translocation at a single-cell level.
The optimized kit, which works with cultured cell lines and whole blood cells, conveniently contains directly-conjugated anti-Human NFкB monoclonal antibody, 7-AAD dye and required buffers. Using the dedicated Nuclear Localization Wizard in the IDEAS software, NFкB translocation can then be studied and quantified in an objective, statistically robust manner. The kit is designed for use with the Amnis® ImageStream®X Mark II and the Amnis® FlowSight® imaging flow cytometers, systems which combine the quantitative power of flow cytometry with the spatial information provided by microscopy.
"With a central role in many cellular responses and human diseases, NFкB continues to be an attractive target for drug discovery," said Patrick Schneider, Ph.D., Head of Bioscience. "Availability of the Amnis® imaging flow systems in combination with the new NFкB Translocation kit provides immunology and cell biology researchers an easier, higher throughput way to further explore the mechanisms of action of this important transcription factor and reveal insights into targeting its signaling pathway for therapeutic purposes."
For more information, please visit www.merckmillipore.com/amnis.